Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q3 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $20.45 million versus the consensus estimate of $20.97 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.